

Editorial

From Algorithms to Insight: The Transformative Power of Artificial Intelligence and Machine Learning in Urological Cancer Research

Matthias May ^{1,*}, Sabine Brookman-May ^{2,3} and Emily Rinderknecht ^{4,†} 

¹ Department of Urology, St. Elisabeth Hospital Straubing, 94315 Straubing, Germany

² Department of Urology, LMU University Hospital, Ludwig Maximilian University of Munich, 81377 Munich, Germany

³ Aura Biosciences, Boston, MA 02135, USA

⁴ Department of Urology, St. Josef Medical Center, University of Regensburg, 93053 Regensburg, Germany

* Correspondence: matthias.may@klinikum-straubing.de

† All authors are included in the Working Group on Artificial Intelligence and Digitalization of the German Society of Urology.

As we advance into a new era of oncological science, artificial intelligence (AI) is no longer a peripheral tool—it is a central agent of change. Nowhere is this transformation more profound and more urgently needed than in urologic oncology, a field that has emerged as one of the most dynamic and innovation-driven domains in contemporary cancer research [1]. Here, the imperatives of precision, personalization, and prognostication converge at unprecedented velocity. AI, in its various incarnations, from classical machine learning to cutting-edge multimodal foundation models, is not merely enhancing traditional methods; it is reshaping the epistemological foundations of cancer research.

Over the past decade, machine learning has matured from experimental prototypes to clinically embedded systems. Deep convolutional neural networks are now widely used to classify prostate lesions on multiparametric magnetic resonance imaging according to PI-RADS criteria, thereby reducing interobserver variability and improving the detection of clinically significant tumors [2–4]. More recent innovations, including Vision Transformers (ViTs) and hybrid models trained on multicenter data, offer refined differentiation between aggressive and indolent lesions—even in diagnostically ambiguous cases.

These are more than computational achievements; they represent cognitive accelerators that increase diagnostic confidence and shorten decision-making timelines [5].

The impact of AI in histopathology is equally transformative. Deep learning models trained on digitized whole-slide images now match or even exceed expert pathologists in Gleason grading accuracy [6,7], thereby offering a scalable solution to workforce limitations. Beyond automation, these systems unlock new frontiers: they can detect architectural and cytological features too subtle for the human eye, paving the way for novel digital biomarkers and redefined prognostic frameworks. In doing so, AI shifts histopathology from visual estimation to data-driven precision.

AI is also transforming the molecular landscape of urologic oncology. Techniques like unsupervised clustering and dimensionality reduction are now applied to high-dimensional transcriptomic and proteomic data, revealing novel therapeutic targets and resistance pathways. One of the most promising intersections is radiogenomics—where imaging features are linked with underlying molecular signatures [8]. This fusion of modalities, feasible only through AI, is already yielding results. In clear cell renal cell carcinoma,



Received: 8 May 2025

Accepted: 12 May 2025

Published: 14 May 2025

Citation: May, M.; Brookman-May, S.; Rinderknecht, E. From Algorithms to Insight: The Transformative Power of Artificial Intelligence and Machine Learning in Urological Cancer Research. *Curr. Oncol.* **2025**, *32*, 277. <https://doi.org/10.3390/currncol32050277>

Copyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

radiogenomic algorithms have accurately predicted VHL mutations and angiogenic profiles, enabling non-invasive molecular profiling with unprecedented precision [8,9].

Perhaps AI's most transformative contribution lies in its power to integrate. Multi-modal models now combine imaging, histopathology, molecular profiles, and electronic health data to create detailed individualized patient representations. These digital phenotypes go far beyond conventional endpoints, offering tailored predictions for recurrence, immune response, and quality of life. Large language models (LLMs) such as ChatGPT-4 and Claude 3.5 further extend this integration by streamlining and enhancing clinical workflows and decision-making and facilitating patient communication [10]. In recent studies, these models have produced patient-friendly summaries of urologic cancer trial information that match—or even surpass—those written by clinicians in terms of both clarity and empathy [11–13]. While more validation is needed across diverse patient populations, their potential to democratize oncology communication is clear.

This maturation of AI from proof of concept to clinical co-pilot is now producing a new generation of decision-support tools that extend beyond static prediction. By continuously integrating patient-specific variables, these systems support individualized treatment planning, real-time tumor board discussions, and nuanced risk stratification grounded in probabilistic reasoning [11–15]. Nevertheless, early randomized studies make it clear that technical sophistication alone does not guarantee improved outcomes. Without thoughtful integration into clinical workflows and adaptation by end-users, even the most accurate algorithms may fall short in practice [16]. The transition from retrospective validation to prospective, real-world implementation marks a fundamental shift—one that redefines the dynamic between algorithmic guidance and clinical judgment.

AI is also poised to reshape the architecture of experimental research itself. In silico hypothesis generation, AI-assisted trial recruitment, adaptive randomization frameworks, and truly adaptive trial designs may significantly reduce the inefficiencies that lead to high attrition and slow accrual. LLMs trained extensively on trial protocols and biomedical literature now support the conceptual design of randomized clinical trials (RCTs) by rapidly assessing endpoint validity, inclusion criteria, internal consistency, and statistical feasibility [17]. What once took weeks can now be accomplished in a fraction of the time. Looking ahead, the AI-enabled simulation of trial scenarios and outcomes across virtual cohorts could optimize eligibility criteria and estimate effect sizes based on real-world data, thereby enhancing both scientific precision and ethical responsibility. Beyond trial design, AI is also transforming operational layers of trial execution, including site selection and feasibility assessment, leveraging real-world data to identify high-performing centers. AI-driven models also forecast recruitment trajectories in real time, allowing dynamic adjustments such as targeted outreach or expanded site activation. Molecular pre-screening tools, integrated with EHR and genomic data, streamline trial matching and stratification. At the endpoint level, AI is helping validate novel digital biomarkers, thereby offering more sensitive and earlier readouts of treatment efficacy or toxicity. Finally, predictive algorithms can inform adaptive interim analyses and signal futility or success earlier than fixed schedules.

Federated learning introduces a new paradigm, enabling institutions to collaboratively train models on decentralized datasets without compromising patient confidentiality. This approach fosters the development of rare urologic cancer models (such as for patients with penile cancer) across international cohorts, maintaining stringent data privacy, a necessity given the biological and logistical heterogeneity that defines urologic oncology [18].

One of the most visionary innovations emerging at the intersection of AI and urologic cancer care is the concept of the digital twin: a dynamic, virtual model of an individual patient, built from real-time, multiscale data inputs. These digital avatars could revo-

lutionize preclinical modeling by simulating therapeutic sequences, optimizing dosing strategies, and predicting long-term outcomes before any treatment is delivered [19]. Although still experimental, digital twins represent a shift toward a truly proactive, precision medicine. Their success will rely on advances in mechanistic modeling, systems biology, and improved interpretability of increasingly complex algorithmic architectures [20].

However, with great power comes great responsibility. AI's potential can tempt us toward algorithmic overconfidence. Models trained on biased or incomplete data can perpetuate health disparities and reinforce systemic inequities. Regulatory frameworks are still catching up, struggling to match the pace of innovation. The opacity of “black box” systems, despite their accuracy, can erode clinical trust and accountability. As AI-generated manuscripts and synthetic datasets become more common, the need to safeguard scientific integrity and trust becomes a moral imperative. In this context, editorial stewardship gains renewed urgency and ethical weight. Journals like *Current Oncology* must not only spotlight innovation but also scrutinize it and favor studies that combine technical excellence with transparency, patient relevance, and ethical reflection. Peer review must evolve accordingly, becoming more multidisciplinary, ethically grounded, and data-literate.

The integration of AI into urologic oncology is not merely a technological evolution; it marks a profound philosophical inflection point. We are moving from empirical observation to predictive modeling, from retrospective analysis to anticipatory insight, and from human-exclusive interpretation to a new era of human–machine collaboration. This shift does not weaken clinical agency; it redefines and empowers it. As urologic oncologists, we remain the interpreters of meaning, even as AI reveals patterns and possibilities previously beyond our reach. AI is not the destination—it is a catalyst. Its promise lies not in replacing physicians but in uncovering hidden signals, latent structures, and new therapeutic frontiers. Our responsibility is to harness its capabilities with discernment, apply it to humility, and anchor its use in the ethical foundations that make medicine inherently human. The era of intelligent oncology is here. We must meet it not with hesitation but with clarity, courage, and a steadfast belief that human judgment must always lead.

Conflicts of Interest: Sabine Brookman-May is Senior Vice President and Therapeutic Area Head Urologic Oncology at the pharmaceutical company Aura Biosciences, Inc. Her position does not entail any conflict of interest with this editorial. Other authors declare no conflicts of interest.

References

1. Manini, C.; Larrinaga, G.; Angulo, J.C.; López, J.I. Hot Spots in Urogenital Basic Cancer Research and Clinics. *Cancers* **2025**, *17*, 1173. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
2. Jensen, L.J.; Kim, D.; Elgeti, T.; Steffen, I.G.; Schaafs, L.-A.; Haas, M.; Kurz, L.J.; Hamm, B.; Nagel, S.N. Detecting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions Using T2w-Derived Radiomics Feature Maps in 3T Prostate MRI. *Curr. Oncol.* **2024**, *31*, 6814–6828. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
3. Hectors, S.J.; Cherny, M.; Yadav, K.K.; Beksac, A.T.; Thulasidass, H.; Lewis, S.; Davicioni, E.; Wang, P.; Tewari, A.K.; Taouli, B. Radiomics Features Measured with Multiparametric Magnetic Resonance Imaging Predict Prostate Cancer Aggressiveness. *J. Urol.* **2019**, *202*, 498–505. [[CrossRef](#)] [[PubMed](#)]
4. Engel, H.; Nedelcu, A.; Grimm, R.; von Busch, H.; Sigle, A.; Krauss, T.; Schlett, C.L.; Weiss, J.; Benndorf, M.; Oerther, B. Diagnostic performance of a fully automated AI algorithm for lesion detection and PI-RADS classification in patients with suspected prostate cancer. *Radiol. Med.* **2025**, *ahead of print*. [[CrossRef](#)] [[PubMed](#)]
5. Chaurasia, A.K.; Harris, H.C.; Toohey, P.W.; Hewitt, A.W. A generalised vision transformer-based self-supervised model for diagnosing and grading prostate cancer using histological images. *Prostate Cancer Prostatic Dis.* **2025**, *ahead of print*. [[CrossRef](#)] [[PubMed](#)]
6. Oliveira, L.D.; Lu, J.; Erak, E.; Mendes, A.A.; Dairo, O.; Ertunc, O.; Kulac, I.; Valle, J.A.B.-D.; Jones, T.; Hicks, J.L.; et al. Comparison of Pathologist and Artificial Intelligence–based Grading for Prediction of Metastatic Outcomes After Radical Prostatectomy. *Eur. Urol. Oncol.* **2025**, *8*, 9–13. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]

7. Cimadamore, A.; Montironi, R.; Cheng, L.; Lopez-Beltran, A.; Rogers, E.T.; Franzese, C.; Crestani, A.; Giannarini, G. The uropathologist of the future: Getting ready with intelligence for the prostate cancer tsunami. *Pathologica* **2024**, *116*, 267–272. [[CrossRef](#)] [[PubMed](#)]
8. Camps, J.; Jiménez-Franco, A.; García-Pablo, R.; Joven, J.; Arenas, M. Artificial intelligence-driven integration of multi-omics and radiomics: A new hope for precision cancer diagnosis and prognosis. *Biochim. Biophys. Acta BBA-Mol. Basis Dis.* **2025**, *1871*, 167841. [[CrossRef](#)] [[PubMed](#)]
9. Deng, J.; Tu, S.; Li, L.; Li, G.; Zhang, Y. Diagnostic, predictive and prognostic molecular biomarkers in clear cell renal cell carcinoma: A retrospective study. *Cancer Rep.* **2024**, *7*, e2116. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
10. Rinderknecht, E.; von Winning, D.; Kravchuk, A.; Schäfer, C.; Schnabel, M.J.; Siepmann, S.; Mayr, R.; Grassinger, J.; Goßler, C.; Pohl, F.; et al. Modification and Validation of the System Causability Scale Using AI-Based Therapeutic Recommendations for Urological Cancer Patients: A Basis for the Development of a Prospective Comparative Study. *Curr. Oncol.* **2024**, *31*, 7061–7073. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
11. Haas, M.; Saberi, V.; Gossler, C.; Schmelzer, A.; Kravchuk, A.; Breyer, J.; Bründl, J.; Engelmann, S.; Kirschner, C.; Gilfrich, C.; et al. Making prostate cancer research accessible: ChatGPT-4 as a tool to enhance lay communication. *Urologie* **2025**, *ahead of print*. (In German) [[CrossRef](#)] [[PubMed](#)]
12. Ganjavi, C.; Melamed, S.; Biedermann, B.; Eppler, M.B.; Rodler, S.; Layne, E.; Ceil, F.; Gill, I.; Cacciamani, G.E. Generative artificial intelligence in oncology. *Curr. Opin. Urol.* **2025**, *35*, 205–213. [[CrossRef](#)] [[PubMed](#)]
13. Waters, M. AI meets informed consent: A new era for clinical trial communication. *JNCI Cancer Spectr.* **2025**, *9*, pkaf028. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
14. Santos, C.S.; Amorim-Lopes, M. Externally validated and clinically useful machine learning algorithms to support patient-related decision-making in oncology: A scoping review. *BMC Med. Res. Methodol.* **2025**, *25*, 45. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
15. Macri, R.; Roberts, S.L. The Use of Artificial Intelligence in Clinical Care: A Values-Based Guide for Shared Decision Making. *Curr. Oncol.* **2023**, *30*, 2178–2186. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
16. Mazor, T.; Farhat, K.S.; Trukhanov, P.; Lindsay, J.; Galvin, M.; Mallaber, E.; Paul, M.A.; Hassett, M.J.; Schrag, D.; Cerami, E.; et al. Clinical Trial Notifications Triggered by Artificial Intelligence–Detected Cancer Progression: A Randomized Trial. *JAMA Netw. Open* **2025**, *8*, e252013. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
17. Layne, E.; Olivas, C.; Hershenhouse, J.; Ganjavi, C.; Ceil, F.; Gill, I.; Cacciamani, G.E. Large language models for automating clinical trial matching. *Curr. Opin. Urol.* **2025**, *35*, 250–258. [[CrossRef](#)] [[PubMed](#)]
18. Rieke, N.; Hancox, J.; Li, W.; Milletari, F.; Roth, H.R.; Albarqouni, S.; Bakas, S.; Galtier, M.N.; Landman, B.A.; Maier-Hein, K.; et al. The future of digital health with federated learning. *NPJ Digit. Med.* **2020**, *3*, 119. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
19. Shen, S.; Qi, W.; Liu, X.; Zeng, J.; Li, S.; Zhu, X.; Dong, C.; Wang, B.; Shi, Y.; Yao, J.; et al. From virtual to reality: Innovative practices of digital twins in tumor therapy. *J. Transl. Med.* **2025**, *23*, 348. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
20. Fountzilias, E.; Pearce, T.; Baysal, M.A.; Chakraborty, A.; Tsimberidou, A.M. Convergence of evolving artificial intelligence and machine learning techniques in precision oncology. *NPJ Digit. Med.* **2025**, *8*, 75. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.